489460.Kq
The company operates in the pharmaceuticals industry, generating revenue primarily through the development, production, and sale of pharmaceutical products.
Business. The company operates in the pharmaceuticals industry, generating revenue primarily through the development, production, and sale of pharmaceutical products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the pharmaceuticals industry, generating revenue primarily through the development, production, and sale of pharmaceutical products.
The company maintains a strong liquidity position, with a current ratio of 30.2 and cash and equivalents amounting to KRW 11,641,966,830. The debt-to-equity ratio is 0.01, indicating a low reliance on debt financing. The price-to-book ratio is 1.62, and the price-to-tangible-book ratio is also 1.62, suggesting that the company's market value is in line with its tangible book value.
Profitability metrics show a return on equity of 6.7% and a return on assets of 6.51%, which are key indicators of the company's efficiency in generating returns from its equity and asset base. The operating margin, calculated as operating income divided by revenue, is 14.84%, which is a strong performance in the pharmaceutical industry.
The company's revenue is concentrated in a single business segment, as disclosed in the financial snapshot. There is no geographic breakdown provided in the available data, but the company's operations are likely centered in its home market. The lack of geographic diversification may pose a concentration risk, as the company's performance is closely tied to the economic and regulatory environment of its primary market.
The company's growth trajectory is positive, with a revenue of KRW 28,490,907,890 in the latest period. The outlook for the current fiscal year is favorable, with a projected increase in revenue. The company's free cash flow of KRW 4,140,282,220 indicates a strong ability to fund operations and invest in growth opportunities.
Risk factors for the company are low, with no immediate filing-based liquidity or dilution flags detected. The dilution potential is also low, as the number of shares outstanding for both basic and diluted scenarios is the same. The company's financial structure and performance suggest a stable and low-risk profile.
Recent events and filings do not indicate any significant changes in the company's operations or financial position. The company's financial statements and disclosures are consistent with a stable and well-managed business. There are no notable recent events that would suggest a shift in the company's strategic direction or financial health.
- The company has a strong liquidity position with a high current ratio and significant cash reserves.
- Profitability metrics such as return on equity and return on assets are favorable, indicating efficient use of capital.
- The company's revenue is concentrated in a single business segment, which may pose a concentration risk.
- The company's growth trajectory is positive, with a strong free cash flow position.
- Risk factors are low, with no immediate liquidity or dilution concerns.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- 489460.KQ Market data — financials · 2026-05-26